TU-100

Phase 2Small molecule

TTsumura USA

TU-100 is one of 9 small molecule programs targeting Ileus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IleusNot yet recruiting

IleusPhase 2

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Ileus

#DrugCompanyPhaseTrials

Entereg

Merck & Co.

Approved

2 2

Resotran

Relistor

Movantik

AAveritas Pharma, Inc.

Cyklokapron

Dilaudid

RRhodes Pharmaceuticals, L.P.

Marcaine

Xylocaine

TU-100

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Ileus

NCT07765589

Clinical

Trials by Indication[1]

Enhanced Recovery After Surgery1 trial

Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection

Completed·TTsumura USA·Phase 2·NCT04742907·402 enrolled

Irritable Bowel Syndrome1 trial

A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

Completed·TTsumura USA·Phase 2·NCT02074579·101 enrolled

Safety and Efficacy1 trial

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Terminated·TTsumura USA·Phase 2·NCT01388933·79 enrolled

Ileus1 trial

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100, Adjunctive to an Enhanced Recovery After Surgery (ERAS) Pathway, to Accelerate Gastrointestinal Recovery in Subjects Undergoing Major Abdominopelvic Surgery (Radical Cystectomy [RC] and Complex Abdominal Wall Reconstruction [CAWR])

Not yet recruiting·TTsumura USA·Phase 2·NCT07765589·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TU-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TU-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TU-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tsumura USA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTsumura USA

TU-100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Enhanced Recovery After Surgery1 trial

Irritable Bowel Syndrome1 trial

Safety and Efficacy1 trial

Ileus1 trial

References

Drug Info

Quick Facts

Related News